Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation
This article was originally published in The Pink Sheet Daily
You may also be interested in...
Lilly Brings Non-Inferiority Data To GLP-1 Show Down
In the competitive GLP-1 market, non-inferiority data against Novo Nordisk’s market-leading Victoza will go a long way toward strengthening the commercial case for Lilly’s once-weekly GLP-1, dulaglutide, pending at FDA.
Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline
The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.
Lilly Discusses GLP-1 Strategy At ADA, Readies For Dulaglutide Filing
The company expects to present dulaglutide as another option for patients and expand the market instead of trying to switch patients already using GLP-1s, but analysts are interested in how it stacks up against the competition.